Evidence map›Paper›PMID 35545877›Full record

ArticleThe Analyst2022

Rapid identification of human muscle disease with fibre optic Raman spectroscopy.

James J P Alix, Maria Plesia, Gavin R Lloyd, Alexander P Dudgeon, Catherine A Kendall, Channa Hewamadduma, Marios Hadjivassiliou, Christopher J McDermott, Gráinne S Gorman, Robert W Taylor and 2 more

Open access · hybridAbstract read
In one paragraph

Article in The Analyst, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

James J P AlixSheffield Institute for Translational Neuroscience, University of Sheffield, UK. j.alix@sheffield.ac.uk.ORCID http://orcid.org/0000-0001-8391-9749
Maria PlesiaSheffield Institute for Translational Neuroscience, University of Sheffield, UK. j.alix@sheffield.ac.uk.
Gavin R LloydPhenome Centre Birmingham, University of Birmingham, UK.
Alexander P DudgeonBiophotonics Research Unit, Gloucestershire Hospitals NHS Foundation Trust, UK.ORCID http://orcid.org/0000-0002-4536-1147
Catherine A KendallBiophotonics Research Unit, Gloucestershire Hospitals NHS Foundation Trust, UK.
Channa HewamaddumaSheffield Institute for Translational Neuroscience, University of Sheffield, UK. j.alix@sheffield.ac.uk.
Marios HadjivassiliouDepartment of Neurology, Sheffield Teaching Hospitals NHS Foundation Trust, UK.
Christopher J McDermottSheffield Institute for Translational Neuroscience, University of Sheffield, UK. j.alix@sheffield.ac.uk.
Gráinne S GormanWellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.ORCID http://orcid.org/0000-0002-7585-3409
Robert W TaylorWellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.ORCID http://orcid.org/0000-0002-7768-8873
Pamela J ShawSheffield Institute for Translational Neuroscience, University of Sheffield, UK. j.alix@sheffield.ac.uk.ORCID http://orcid.org/0000-0002-8925-2567
John C C DayInterface Analysis Centre, School of Physics, University of Bristol, UK.ORCID http://orcid.org/0000-0002-1719-5065
University of Sheffield · GBNewcastle upon Tyne Hospitals NHS Foundation Trust · GBSheffield Teaching Hospitals NHS Foundation Trust · GBGloucestershire Hospitals NHS Foundation Trust · GBUniversity of Birmingham · GBUniversity of Bristol · GBUniversity of Exeter · GB

Funding

Medical Research Council MC_PC_15034Medical Research Council MR/S005021/1Wellcome Trust
6 · The paper itself

Abstract

The diagnosis of muscle disorders ("myopathies") can be challenging and new biomarkers of disease are required to enhance clinical practice and research. Despite advances in areas such as imaging and genomic medicine, muscle biopsy remains an important but time-consuming investigation. Raman spectroscopy is a vibrational spectroscopy application that could provide a rapid analysis of muscle tissue, as it requires no sample preparation and is simple to perform. Here, we investigated the feasibility of using a miniaturised, portable fibre optic Raman system for the rapid identification of muscle disease. Samples were assessed from 27 patients with a final clinico-pathological diagnosis of a myopathy and 17 patients in whom investigations and clinical follow-up excluded myopathy. Multivariate classification techniques achieved accuracies ranging between 71-77%. To explore the potential of Raman spectroscopy to identify different myopathies, patients were subdivided into mitochondrial and non-mitochondrial myopathy groups. Classification accuracies were between 74-89%. Observed spectral changes were related to changes in protein structure. These data indicate fibre optic Raman spectroscopy is a promising technique for the rapid identification of muscle disease that could provide real time diagnostic information. The application of fibre optic Raman technology raises the prospect of

Indexed as

Muscular DiseasesSpectrum Analysis, RamanFiber Optic TechnologyHumansMuscles

Identifiers

PMID35545877
PMCPMC9150427
OpenAlexW4226338063

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.